Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a
global public health threat. A significant challenge for TB control efforts has been the …

We currently have a binomial approach to managing tuberculosis. Those with active
disease, ideally confirmed microbiologically, are treated with a standard 6-month, multi-drug …

The pathogen Mycobacterium tuberculosis (Mtb), causing tuberculosis disease, features an
extraordinary thick cell envelope, rich in Mtb-specific lipids, glycolipids, and glycans. These …

BACKGROUND Inadequate tuberculosis (TB) diagnostics are a major hurdle in the
reduction of disease burden, and accurate point-of-care tests (POCTs) are urgently needed …

Background Sputum is the most widely used sample to diagnose active tuberculosis, but
many people living with HIV are unable to produce sputum. Urine, in contrast, is readily …

An estimated one-third of tuberculosis (TB) cases go undiagnosed or unreported. Sputum
samples, widely used for TB diagnosis, are inefficient at detecting infection in children and …

Antiretroviral therapy (ART), while essential in combatting tuberculosis (TB) and HIV
coinfection, is often complicated by the TB-associated immune reconstitution inflammatory …

Tuberculosis (TB) is still a severe public health problem; the current diagnostic tests have
limitations that delay treatment onset. Lipoarabinomannan (LAM) is a glycolipid that is a …

Background: Since 2015, the World Health Organization (WHO) has recommended a
commercially available lateral-flow urine LAM test (Alere-LAM) to assist in the diagnosis of …

Antibodies to the mycobacterial surface lipoglycan lipoarabinomannan (LAM) and its related
capsular polysaccharide arabinomannan (AM) are increasingly important for investigations …